Basilea Pharmaceutica
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hegenheimermattweg 167b, Allschwil, Base...Phone Number
+41 616061111Website
www.basilea.comRevenue
$187.5 MillionStock Symbol
BSLNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Basilea Pharmaceutica
Founded in 2000, Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that specializes in the development of products for the therapeutic areas of oncology and infectious diseases. Basilea Pharmaceutica is located in Switzerland.Explore more
Basilea Pharmaceutica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Basilea Pharmaceutica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Basilea Pharmaceutica, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Basilea Pharmaceutica is spiking on competitors!
Funding: Get notified immidiatlly once Basilea Pharmaceutica has new funding data
Earning: See what the market has to say on Basilea Pharmaceutica recently announced quarterly report
Check if Basilea Pharmaceutica has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Basilea Pharmaceutica
Click to see if Basilea Pharmaceutica had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Basilea Pharmaceutica launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Basilea Pharmaceutica
Find 2 more new buyers
Company Profile Activity
Activity Insights
Basilea Pharmaceutica is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Basilea Pharmaceutica is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Basilea Pharmaceutica.
Basilea Pharmaceutica Tech Stack
A closer look at the technologies used by Basilea Pharmaceutica
Most Recent Scoops
Earnings
Basilea Pharmaceutica has repurchased CHF 5 million in nominal value of its convertible bonds during H1 2026, reducing the outstanding nominal balance to CHF 71 million, with the convertible bond due to mature in July 2027.
Finance, Financing & Debt
Earnings
Basilea Pharmaceutica has reported that Cresemba and Zevtera-related revenue totaled CHF 92.3 million for H1 2026, comprising royalty income of CHF 57.8 million (up approximately 11% year-on-year), milestone and upfront payments of CHF 4.7 million, and other revenue of CHF 26.7 million, primarily from BARDA and CARB-X reimbursements.
Earnings, Finance
Earnings
now expects total revenue for full year 2026 to grow by approximately 15%, with Cresemba and Zevtera-related revenue projected at approximately CHF 210 million, and has raised its operating profit guidance to approximately 40% growth year-on-year, up from a prior expectation of approximately 20% growth.
Earnings, Finance
Earnings
expects full year 2026 Cresemba and Zevtera-related revenues to comprise approximately CHF 125 million from royalties, CHF 35 million from milestone payments, and CHF 50 million from product revenue, with the revenue mix expected to continue shifting toward higher-margin royalties and milestones.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Earnings, Accounting, Financial Reporting, Finance
Basilea Pharmaceutica News & Media
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
Ad hoc announcement pursuant to Art. 53 LRBasilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LRBasilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
Ad hoc announcement pursuant to Art. 53 LRBasilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
US BARDA awarded Basilea USD 13.3 million to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Basilea Pharmaceutica
Sign Up For FreeTo access detailed company insights
Founded in 2000, Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that specializes in the development of products for the therapeutic areas of oncology and infectious diseases. Basilea Pharmaceutica is located in Switzerland.... Read More
